NRF1 and melanoma: Our analysis demonstrates that NRF1 downregulation leads to the significantly reduced proportion of melanoma cells expressing high levels of this innate immunity checkpoint when compared to the original cell population trasduced with control SC-siRNA: 7.04% CD47high//91.8% CD47low for NRF1-siRNA and 34.3% CD47hig//64.1% CD47low for SC-RNAi transduced cells (Figure 6D).